Invitrogen™ CD199 (CCR9) Monoclonal Antibody (BBC3M4), eFluor™ 660, eBioscience™, 100 Tests

The Invitrogen™ CD199 (CCR9) Monoclonal Antibody (BBC3M4), eFluor™ 660, eBioscience™ (Catalog # 50-1999-42) is a high-performance reagent designed for precise detection of CD199 (CCR9) in human immune cells using flow cytometry. This eFluor™ 660-conjugated antibody enables clear identification of CCR9-expressing T cells, which play a key role in mucosal immunity and gut-homing responses.

Key Features & Benefits

1. High-Specificity Detection of CD199 (CCR9)

• Targets human CCR9, a chemokine receptor essential for T-cell homing to mucosal tissues.
• Recognizes gut-homing T-cell subsets, particularly CD4+ and CD8+ T cells.
• Supports flow cytometry-based analysis of immune cell trafficking and mucosal immune responses.

2. eFluor™ 660 Conjugation for High-Sensitivity Flow Cytometry

• Conjugated to eFluor™ 660 (Excitation: 651 nm / Emission: 668 nm) for strong fluorescence detection.
• Optimized for red laser (633–647 nm), minimizing spectral overlap in multicolor panel design.
• Provides bright, photostable staining for reproducible flow cytometry analysis.

3. Optimized for Flow Cytometry Immunophenotyping

• Pre-titrated and validated for 5 μL (0.25 μg)/test, ensuring consistent results.
• Recommended for gating of CD199-expressing lymphocytes in flow cytometry experiments.
• Compatible with fluorescence compensation controls and multicolor panels.

4. Fixation-Compatible & Long-Term Stability

• Works with fixation buffers (IC Fixation Buffer, 1-Step Fix/Lyse Solution) for sample storage up to 3 days.
• Stable at 4°C in the dark, preventing fluorophore photobleaching.

Product Specifications

Available Variants & Ordering Information

Applications & Use Cases

1. Immunophenotyping of Gut-Homing T Cells

• Characterization of CCR9-expressing T-cell subsets in mucosal immunity research.
• Analysis of gut-homing lymphocytes responding to retinoic acid and CCL25.
• Works in multicolor panels with CD4, CD8, and Integrin Beta 7 markers.

2. Inflammatory Bowel Disease (IBD) & Autoimmune Research

• Studying CCR9-mediated T-cell migration in Crohn’s disease and ulcerative colitis.
• Investigating immune cell trafficking in chronic inflammation & autoimmune disorders.

3. Tumor Immunology & Cancer Research

• Assessment of CCR9+ T cells in gastrointestinal tumors and mucosal-associated malignancies.
• Evaluation of integrin & chemokine receptor interactions in tumor microenvironments.

4. Vaccine Development & Infectious Disease Studies

• Analysis of CCR9-dependent immune responses in gastrointestinal infections.
• Studying mucosal T-cell activation following vaccination.

Performance Data & Validation

1. High-Purity Staining for Flow Cytometry

• Validated on stimulated human peripheral blood cells, showing strong, specific staining of CCR9-expressing T cells.
• Enables clear gating of CCR9+ lymphocyte populations.

2. Multicolor Panel Compatibility

• Works alongside Integrin Beta 7 (CD103), CD3, CD4, and CD8 markers for detailed immune profiling.
• Ensures bright fluorescence signal with minimal spillover, making it ideal for complex flow cytometry panels.

Target Information: CD199 (CCR9)

CD199 (CCR9) is a G-protein-coupled chemokine receptor that directs T-cell migration to the gut. It binds to CCL25 (TECK) and plays a key role in:

• T-cell homing to the small intestine.
• Thymocyte development and immune cell recruitment to mucosal tissues.
• Regulating immune responses in gut-associated lymphoid tissues (GALT).

Aliases

• C-C Chemokine Receptor Type 9 (CCR9)
• CDw199, GPR9-6, GPR28

UniProt ID

• Human: P51686

The Invitrogen™ CD199 (CCR9) Monoclonal Antibody (BBC3M4), eFluor™ 660 is a high-performance flow cytometry antibody designed for detection of gut-homing T cells and mucosal immune responses. Featuring eFluor™ 660 conjugation for strong fluorescence signal, validated specificity for human CCR9, and compatibility with multicolor flow cytometry panels, this antibody is ideal for immunophenotyping, inflammatory disease research, tumor immunology, and vaccine development.